Medtronic (NYSE:MDT) today announced new clinical findings supporting its Aurora EV-ICD system and OmniaSecure defibrillation ...

The subcutaneous implantable cardioverter–defibrillator (ICD) is associated with fewer lead-related complications than a transvenous ICD; however, the subcutaneous ICD cannot provide bradycardia and ...

The extravascular implantable cardioverter–defibrillator (ICD) has a single lead implanted substernally to enable pause-prevention pacing, antitachycardia pacing, and defibrillation energy similar to ...

Biotronik announced today that it received FDA approval for its Acticor Sky and Rivacor implantable defibrillator systems.

Abbott is teaming up with AtaCor Medical to develop a next-generation implantable cardioverter defibrillator (ICD) designed to treat dangerous cardiac arrhythmias without routing wires through the ...

Please provide your email address to receive an email when new articles are posted on . A novel implantable cardioverter defibrillator platform may benefit patients with HF not eligible for cardiac ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A leadless pacing-defibrillator system was safe and met ...

MINNEAPOLIS — Switching candidates for implantable cardioverter-defibrillator (ICD) implantation to a dual-function device that also modulates cardiac contractility was associated with successful ...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System ...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. announced today that it has completed enrollment in its initial acute Extravascular Implantable Cardioverter Defibrillator (EV-ICD) study.